Chiffres en millions de dollars américains. L'exercice financier va de février à janvier.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenus
1,506
1,946
2,010
2,120
1,257
416
Croissance des revenus (H/H)
-30%
-3%
-5%
69%
202%
136%
Coût des ventes
950
939
1,017
1,031
688
199
Bénéfice brut
556
1,007
993
1,089
569
216
Vente, Général et Administration
465
795
831
1,162
669
230
Recherche et développement
102
165
227
--
--
--
Frais d'exploitation
782
1,289
1,112
1,364
806
268
Autres revenus (charges) non opérationnels
0
0
-3
-10
-5
--
Bénéfice avant impôts
-1,258
-70
-797
-34
-213
-54
Charge d'impôt sur le revenu
4
23
-8
53
15
-5
Bénéfice net
-683
-5
-1,172
-832
-227
-48
Croissance du bénéfice net
-45%
-100%
41%
267%
373%
-23%
Actions en circulation (diluées)
70.57
70.57
70.57
64.34
57.26
43.85
Variation des actions (H-H)
0%
0%
10%
12%
31%
4%
EPS (dilué)
-9.67
-0.07
-16.61
-12.94
-3.97
-1.09
Croissance du EPS
-45%
-100%
28%
225.99%
262%
-25%
Flux de trésorerie libre
159
72
-112
-799
-676
-213
Flux de trésorerie libre par action
--
--
--
--
--
--
Marge brute
36.91%
51.74%
49.4%
51.36%
45.26%
51.92%
Marge opérationnelle
-15%
-14.49%
-5.92%
-12.92%
-18.77%
-12.25%
Marge bénéficiaire
-45.35%
-0.25%
-58.3%
-39.24%
-18.05%
-11.53%
Marge du flux de trésorerie libre
10.55%
3.69%
-5.57%
-37.68%
-53.77%
-51.2%
EBITDA
983
196
1,810
666
-45
1
Marge EBITDA
65.27%
10.07%
90.04%
31.41%
-3.57%
0.24%
D&A pour le résultat opérationnel
1,209
478
1,929
940
191
52
EBIT
-226
-282
-119
-274
-236
-51
Marge EBIT
-15%
-14.49%
-5.92%
-12.92%
-18.77%
-12.25%
Taux d'imposition effectif
-0.31%
-32.85%
1%
-155.88%
-7.04%
9.25%
Statistiques clés
Clôture préc.
$0.375
Prix d'ouverture
$0.375
Plage de la journée
$0.375 - $0.375
Plage de 52 semaines
$0.375 - $0.9
Volume
6.0K
Volume moyen
462
BPA (TTM)
-0.50
Rendement en dividend
--
Capitalisation boursière
$25.9M
Qu’est-ce que BICO GROUP AB ?
BICO Group AB engages in the provision of technologies, products, and services to create, understand, and master biology. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 586 full-time employees. The company went IPO on 2016-11-03. The firm focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The firm develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.